Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab. Reumatismo [Internet]. 2025 Jun. 26 [cited 2025 Jun. 27];. Available from: https://www.reumatismo.org/reuma/article/view/1792